Roche has expanded its global AI infrastructure with the launch of a large-scale “AI factory,” built on advanced accelerated computing systems from NVIDIA, as it seeks to speed up drug discovery and diagnostics development.

The new setup includes 2,176 high-performance GPUs deployed across facilities in the United States and Europe, integrated across Roche’s operations from research to manufacturing. With this addition, the company’s combined on-premises and cloud infrastructure now exceeds 3,500 Blackwell GPUs — marking what it describes as the largest announced GPU deployment in the pharmaceutical sector.

The expansion builds on Roche’s ongoing collaboration with NVIDIA, which began in 2023, and is aimed at using AI to shorten development timelines and improve scientific outcomes.

“In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner,” said Wafaa Mamilli, Roche’s Chief Digital and Technology Officer. “Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain — from discovery to development, manufacturing, and commercialization — transforming how we deliver the next generation of medicines and diagnostic solutions.”

The AI factory functions as a high-performance computing platform supporting a range of use cases. In research, it powers AI-driven experimentation through connected lab systems. In manufacturing, it enables digital twins to optimize production processes. In diagnostics and digital pathology, it processes large datasets to identify disease patterns, while also supporting conversational AI tools designed for healthcare environments.